ARIXTRA is a Factor Xa inhibitor (anticoagulant) indicated for:
• Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery.
• Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin.

The most common adverse reactions associated with the use of ARIXTRA are bleeding complications. Mild local irritation (injection site bleeding, rash, and pruritus) may occur following subcutaneous injection.
Anemia, insomnia, increased wound drainage, hypokalemia, dizziness, hypotension, confusion, bullous eruption, hematoma, post-operative hemorrhage, and purpura may occur.

Discontinue agents that may enhance the risk of hemorrhage prior to initiation of therapy with ARIXTRA unless essential. If co-administration is necessary,monitor patients closely for hemorrhage.

• Use with caution in patients who have conditions or who are taking concomitant medications that increase risk of hemorrhage.
• Bleeding risk is increased in renal impairment and in patients with low body weight.
• Thrombocytopenia can occur with administration of ARIXTRA.
• Periodic routine complete blood counts (including platelet counts), serum creatinine level and stool occult blood tests are recommended
• The packaging (needle guard) contains dry natural rubber and may cause allergic reactions in latex sensitive individuals